Abstract
Hypofibrinogenaemia is associated with increased morbidity and mortality, but the optimal treatment level, the use of preemptive treatment and the preferred source of fibrinogen remain disputed. Fibrinogen concentrate is increasingly used and recommended for bleeding with acquired haemostatic deficiencies in several countries, but evidence is lacking regarding indications, dosing, efficacy and safety.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Cochrane Database of Systematic Reviews |
Vol/bind | 8 |
Sider (fra-til) | CD008864 |
ISSN | 1469-493X |
DOI | |
Status | Udgivet - 2013 |